When Dr. Pnina Fishman discovered that cancer doesn’t attack striated muscle tissue, she knew she was onto something. So she founded Can-Fite BioPharma (NYSE MKT: CANF) and went to work using this information to develop cancer treatments.
Can-Fite’s liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the FDA. It has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma.
Can-Fite has an advanced pipeline of proprietary orally available compounds in Phase II and III clinical development that also target:
- Non-alcoholic fatty liver disease (NAFLD)
- Erectile Disfunction (ED)
Join our webinar on February 24 to hear from Can-Fite CEO, Dr. Pnina Fishman to learn more about this innovative company and all the projects in their pipeline.
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.